Imbruvica-话题@MedSci

#Imbruvica#

14篇内容 | 955人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1312499, encodeId=341013124994a, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, objectType=article, longId=184955, objectId=41c3184955ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c3184955ce, replyNumber=0, likeNumber=34, createdTime=2019-12-21, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c3184955ce, moduleTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c3184955ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312498, encodeId=27ae13124980e, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, objectType=article, longId=177713, objectId=d3701e7713cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3701e7713cf, replyNumber=0, likeNumber=38, createdTime=2019-08-17, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3701e7713cf, moduleTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3701e7713cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312497, encodeId=2a9e131249eff, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病, objectType=article, longId=159146, objectId=e3eb15914659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3eb15914659, replyNumber=0, likeNumber=38, createdTime=2019-01-30, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3eb15914659, moduleTitle=Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3eb15914659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312496, encodeId=2085131249698, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, objectType=article, longId=158889, objectId=58081588897d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58081588897d, replyNumber=0, likeNumber=0, createdTime=2019-01-27, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58081588897d, moduleTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58081588897d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312495, encodeId=9537131249596, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=Janssen的Imbruvica最终被纳入NHS, objectType=article, longId=128592, objectId=60f6128592c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60f6128592c9, replyNumber=0, likeNumber=0, createdTime=2018-02-03, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60f6128592c9, moduleTitle=Janssen的Imbruvica最终被纳入NHS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60f6128592c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312494, encodeId=a515131249472, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功, objectType=article, longId=122645, objectId=70ef12264515, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ef12264515, replyNumber=0, likeNumber=36, createdTime=2017-12-09, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ef12264515, moduleTitle=Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ef12264515)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312493, encodeId=abe9131249338, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=70030, objectId=0f9ae003001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9ae003001, replyNumber=0, likeNumber=40, createdTime=2016-06-07, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9ae003001, moduleTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9ae003001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312492, encodeId=87e11312492f7, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）, objectType=article, longId=67960, objectId=cc206e96084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc206e96084, replyNumber=0, likeNumber=32, createdTime=2016-05-12, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc206e96084, moduleTitle=6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc206e96084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312491, encodeId=26bc1312491fc, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=64673, objectId=6448646e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6448646e38c, replyNumber=0, likeNumber=39, createdTime=2016-03-13, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6448646e38c, moduleTitle=5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6448646e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312490, encodeId=db3013124907e, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持, objectType=article, longId=51482, objectId=da2851482b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da2851482b4, replyNumber=0, likeNumber=36, createdTime=2015-06-03, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da2851482b4, moduleTitle=强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da2851482b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312489, encodeId=a902131248931, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=ASH 2014：Imbruvica使携带del17p突变的CLL患者获益, objectType=article, longId=44418, objectId=20e5444189c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e5444189c, replyNumber=0, likeNumber=51, createdTime=2014-12-24, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e5444189c, moduleTitle=ASH 2014：Imbruvica使携带del17p突变的CLL患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e5444189c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312488, encodeId=92d21312488d4, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=ASH 2014：强生血癌药物Imbruvica在高风险CLL群体表现出强大治疗利益, objectType=article, longId=43996, objectId=e4c04399608, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c04399608, replyNumber=0, likeNumber=32, createdTime=2014-12-14, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c04399608, moduleTitle=ASH 2014：强生血癌药物Imbruvica在高风险CLL群体表现出强大治疗利益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c04399608)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312487, encodeId=f0c8131248ec2, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=强生抗癌药Imbruvica新适应症获FDA批准, objectType=article, longId=30690, objectId=db57306904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db57306904b, replyNumber=0, likeNumber=48, createdTime=2014-02-18, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db57306904b, moduleTitle=强生抗癌药Imbruvica新适应症获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db57306904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312486, encodeId=4c7d131248665, content=<a href='/topic/show?id=dc0c9e5231' target=_blank style='color:#2F92EE;'>#Imbruvica#</a>, objectTitle=FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤, objectType=article, longId=27987, objectId=44192e98757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44192e98757, replyNumber=0, likeNumber=43, createdTime=2013-12-15, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44192e98757, moduleTitle=FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44192e98757)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Imbruvica

2020-05-29

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica

2019-12-21

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症

2019-08-17

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

Imbruvica和Gazyvo联用获FDA批准用于治疗慢性淋巴细胞白血病

2019-01-30

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验

2019-01-27

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

Janssen的Imbruvica最终被纳入NHS

2018-02-03

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功

2017-12-09

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-06-07

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

6个适应症！FDA批准艾伯维突破性药物Imbruvica治疗小淋巴细胞性淋巴瘤（SLL）

2016-05-12

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-03-13

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持

2015-06-03

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

ASH 2014：Imbruvica使携带del17p突变的CLL患者获益

2014-12-24

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

ASH 2014：强生血癌药物Imbruvica在高风险CLL群体表现出强大治疗利益

2014-12-14

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

强生抗癌药Imbruvica新适应症获FDA批准

2014-02-18

syscxl (审核中...)

前往app查看评论内容

#Imbruvica#

FDA批准Imbruvica(Ibrutinib)用于治疗套细胞淋巴瘤

2013-12-15

科室
- - 订阅+
  - 更多科室
工具
服务